<DOC>
	<DOCNO>NCT01390974</DOCNO>
	<brief_summary>To demonstrate strategy fast genetic testing perform outpatient clinic allows select adequately one 2 antiplatelet treatment approve indication ( ACS PCI - prasugrel 10mg MD clopidogrel 75mg MD ) . Patients reach similar level platelet inhibition 2 different thienopyridines suggest optimal risk/benefit ratio patient individualized therapy .</brief_summary>
	<brief_title>Identification Clopidogrel CYP2C19 Metabolizer Thienopyridine Treatment After Acute Coronary Syndrome</brief_title>
	<detailed_description>Rationale : There thresholds on-treatment platelet reactivity appear expose patient either risk thrombotic event ( high on-treatment platelet reactivity ) risk bleed event ( low on-treatment platelet reactivity ) . Clopidogrel oral platelet P2Y12 receptor inhibitor require metabolic activation catalyze several Cytochromes P450 ( CYP ) isoforms . The loss-of-function polymorphism 2C19*2 , carry 30 % individual , associate high-on-treatment platelet reactivity ( low level P2Y12 inhibition ) high risk stent thrombosis patient expose clopidogrel ( OR=3.45 ( 2.14-5.57 ) ) . The gain-of-function polymorphism 2C19*17 associate low-on-treatment platelet reactivity ( high level P2Y12 inhibition ) high risk TIMI major bleeding ( OR=1.85 ( 1.19 -2.86 ) . Prasugrel new thienopyridine drug improve ischemic outcome compare clopidogrel acute coronary syndrome patient undergoing PCI drug also associate bleeding complication . Prasugrel potent irreversible P2Y12inhibitor clopidogrel , also require metabolic conversion less affected CYP2C19 variant , unlike clopidogrel . The recent pharmacogenetic literature suggest individualize treatment ( choice clopidogrel prasugrel possible indication ) base genetic information rapidly obtain , possible . This would improve risk/benefit therapy . Both common gain- loss-of function CYP2C19 allele combine identify two metabolizers status : rapid metabolizer ( ultra fast UF : *17/*17 , 5 % comer normal metabolizers NM : *1/*1 et *1/*17 , 50 % comer ) potential high risk bleed slow metabolizer ( Intermediate Metabolizers IM , *1/*2 *2/*17 , 40 % comer Poor Metabolizers PM , *2/*2 , 5 % comer ) potential high risk thrombosis . Primary hypothesis ( `` genetic hypothesis '' ) : proportion rapid metabolizers treat 75mg clopidogrel MD within optimal range P2Y12 inhibition 30 day , ( define threshold 220 AU·min 350 AU·min ADP-induced platelet aggregation measure Multiple Electrode platelet Aggregometry - Multiplate analyzer , DYNABYTE , Munich , Germany % inhibition 30 % 80 % use VerifyNowTMP2Y12 platform ) , non inferior proportion slow metabolizers treat prasugrel 10mg MD.Secondary hypothesis ( `` functional hypothesis '' ) : At 30 day , patient outside pre-specified target P2Y12 inhibition level adjust ( prasugrel 10mg clopidogrel 75mg ) . The hypothesis PFT top genetic test improve number patient reach prespecified optimal target P2Y12 inhibition . Thus , proportion slow metabolizers within target D45 non inferior rapid metabolizer determine POC PFT . Objectives : To demonstrate strategy fast genetic testing perform outpatient clinic allows select adequately one 2 antiplatelet treatment approve indication ( ACS PCI - prasugrel 10mg MD clopidogrel 75mg MD ) . Patients reach similar level platelet inhibition 2 different thienopyridines suggest optimal risk/benefit ratio patient individualized therapy . Study population : ACS patient recently underwent stent PCI , stable eligible prasugrel clopidogrel therapy.Study design : Prospective , multicenter study . Genetic metabolizer status determine use VerigeneTM ( Nanosphere technology ) platform outpatient follow-up visit . Thienopyridine treatment enrolment affect eligibility . Rapid metabolizers ( UF NM ) treat 75mg clopidogrel MD slow metabolizers ( IM PM ) allocate prasugrel 10mg MD . A first evaluation platelet reactivity perform one month allow comparison proportion patient within optimal prespecified window P2Y12 inhibition ( primary hypothesis ) . The investigator evaluate hypothesis treatment adjustment base result obtain pharmacodynamic evaluation improve rate success . In second phase , patient level P2Y12 inhibition &gt; 80 % ( &lt; 220AU.min ) &lt; 30 % ( &gt; 350 AU.min ) switch 75mg clopidogrel MD prasugrel 10mg MD , respectively . A second evaluation level platelet reactivity perform day 45 allow comparison proportion patient within prespecified optimal window P2Y12 inhibition rapid slow metabolizer genotype . Duration inclusion : 12 month Duration participation patient : 60 day Primary endpoint : Proportion patient within optimal prespecified window P2Y12 inhibition 30 day define threshold 220 AU·min 350 AU·min ADP-induced platelet aggregation measure Multiple Electrode platelet Aggregometry - Multiplate analyzer , DYNABYTE , Munich , Germany % inhibition 30 % 80 % use VerifyNowTMP2Y12 platform.Number patient : The investigator estimate proportion prasugrel-treated patient within prespecified target P2Y12 inhibition 75 % . The investigator formulate hypothesis 80 % rapid metabolizers clopidogrel 75mg MD stand optimal prespecified window P2Y12 inhibition investigator wish demonstrate proportion inferior prasugrel-treated patient . Considering power 80 % , alpha-risk error 0.05 non-inferiority margin -10 % , sample size 122 patient per group require . Expected result : The GAMMA study provide answer major challenge whether rapid genetic information 2C19 genotype help reach optimal target IPA use 2 different thienopyridine , different sensitivity CYP2C19 variant . Statistical analysis : The non inferiority consider demonstrate ( accord consent risk ) non inferiority margin 95 % confidence interval difference percentage superior non inferiority margin ( ICH Statistical Procedures ) . The non-inferiority margin establish -10 % accord clinical consideration base acceptable maximal lose efficacy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>ACS patient underwent Percutaneous coronary intervention Anemia &lt; 10g/dL Indication VKA Recent bleeding plan surgery Thrombopenia &lt; 80 000/µl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>ACS</keyword>
	<keyword>PCI</keyword>
	<keyword>thienopyridines</keyword>
	<keyword>prasugrel therapy</keyword>
	<keyword>clopidogrel therapy</keyword>
</DOC>